OFIX Stock Overview Operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Orthofix Medical Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Orthofix Medical Historical stock prices Current Share Price US$18.33 52 Week High US$20.73 52 Week Low US$12.08 Beta 1.1 1 Month Change 4.98% 3 Month Change 8.08% 1 Year Change 29.91% 3 Year Change -39.43% 5 Year Change -57.87% Change since IPO 74.57%
Recent News & Updates
Orthofix Medical Inc. to Report Q4, 2024 Results on Feb 25, 2025 Jan 28
President recently sold US$327k worth of stock Jan 15
Third quarter 2024 earnings: EPS misses analyst expectations Nov 08
Orthofix Medical Inc. Reiterates Earnings Guidance for Full Year 2024 Nov 08
Levi & Korsinsky, LLP Notifies Investors in Orthofix Medical Inc. of A Class Action Securities Law Oct 15
Orthofix Medical Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 10 See more updates
Orthofix Medical Inc. to Report Q4, 2024 Results on Feb 25, 2025 Jan 28
President recently sold US$327k worth of stock Jan 15
Third quarter 2024 earnings: EPS misses analyst expectations Nov 08
Orthofix Medical Inc. Reiterates Earnings Guidance for Full Year 2024 Nov 08
Levi & Korsinsky, LLP Notifies Investors in Orthofix Medical Inc. of A Class Action Securities Law Oct 15
Orthofix Medical Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 10
Bronstein, Gewirtz & Grossman, LLC Files Lawsuit Against Orthofix Medical Inc. and Seaspine Holdings Corporation Oct 01
No longer forecast to breakeven Sep 30 Scott+Scott Attorneys At Law LLP Files Securities Class Action Lawsuit in the United States District Court for the Eastern District of Texas Against Orthofix Medical, Inc Aug 22
Patrick Fisher Joins Orthofix as President of Global Orthopedics Business Aug 16
Consensus EPS estimates fall by 24% Aug 13
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 07
Orthofix Medical Inc. Revises Revenue Guidance for the Full Year 2024 Aug 07
Orthofix Names Stephanie Walsh as Chief Human Resources Officer Jul 16
Orthofix Medical Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 10
Orthofix Medical Inc. Announces First Implant of Fitbone Transport and Lengthening System Jul 09
Orthofix Medical Inc.(NasdaqGS:OFIX) dropped from Russell 2000 Value-Defensive Index Jul 03
Orthofix Medical Inc. Appoints Michael Finegan as Chair of Board of Directors Jun 24
Orthofix Medical Inc. Appoints Aviva Mcpherron as President of Global Operations and Quality Jun 19
Orthofix Medical Inc. Appoints Max Reinhardt as President of Global Spine Business Effective June 10, 2024 May 24
Orthofix Medical Inc. Announces FDA 510(K) Clearance for the Rodeo Telescopic Nail May 10
Orthofix Medical Inc. Revises Earnings Guidance for the Year 2024 May 09
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 08
Price target increased by 21% to US$21.80 May 07
Consensus EPS estimates upgraded to US$1.27 loss May 07
Orthofix Medical Inc., Annual General Meeting, Jun 18, 2024 May 01
Orthofix Medical Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 24
New minor risk - Profitability Apr 16
Orthofix Medical Inc. Appoints Andres Cedron as New Chief Legal Officer Apr 16
Orthofix Medical Inc. Announces Board Resignation Apr 13
Orthofix Medical Inc. Appoints Lucas Vitale as Chief People and Business Operations Officer Mar 19
Consensus EPS estimates fall by 12% Mar 12
Full year 2023 earnings: EPS misses analyst expectations Mar 06
Orthofix Medical Inc. Provides Earnings Guidance for the Year 2024 Mar 06
Orthofix Medical Inc. to Report Q4, 2023 Results on Mar 05, 2024 Feb 22
Orthofix Medical Inc. Names Massimo Calafiore as President and Member of the Board of Directors Effective Immediately Jan 10 Orthofix Medical Inc. Appoints Julie Andrews as Chief Financial Officer
Orthofix Announces Publication of New Data Supporting Use of PEMF Stimulation in Lumbar Spine Fusion Procedures for Patients at Risk of Pseudarthrosis Dec 21
Orthofix Medical Inc. Announces Board Changes Dec 16 Orthofix Medical Inc. Appoints Massimo Calafiore as Chief Executive Officer, Effective in Early 2024
Consensus EPS estimates upgraded to US$3.50 loss, revenue downgraded Nov 15
Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023 Nov 10
Third quarter 2023 earnings: EPS misses analyst expectations Nov 10
Orthofix Medical Inc. Announces Full Commercial Launch of the Waveform L Interbody System for Lateral Lumbar Fusion Procedures Nov 07
Orthofix Medical Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 19
Orthofix Medical Inc. Announces 510k Clearance and Full Commercial Launch of OsteoCove, an Advanced Bioactive Synthetic Graft for Use in Spine and Orthopedic Procedures Oct 13
Orthofix Medical Inc. Announces First Patient Procedures and Full Commercial Launch of the Galaxy Fixation Gemini System and Expanded Sterile Kit Offerings for Orthopedic Trauma Procedures Sep 21
Independent Director recently bought US$101k worth of stock Sep 17
Orthofix Medical Inc. Announces Management Appointments Sep 15 Orthofix Medical Inc. Announces Management Changes
Price target decreased by 11% to US$29.00 Sep 12
Consensus EPS estimates fall by 12% Aug 15
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 09
Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023 Aug 09
Orthofix Medical Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 26
Price target decreased by 12% to US$32.67 Jul 20
Orthofix Medical Inc. Introduces New Phantom and Tornado Hins for Truelok Ring Fixation Systems Jun 29
Orthofix Medical Inc. Announces Changes to Board of Directors Jun 21
Orthofix Medical Inc Announces the Full Commercial Launch of WaveForm A 3D Printed Anterior Lumbar Interbody Jun 20
Orthofix Medical Inc. Announces First Presentation of Seven-Year Outcome Data for the M6-C Artificial Cervical Disc with Other Clinical and Scientific Abstracts At the Isass Annual Meeting Jun 02
President of Global Spine Business recently sold US$157k worth of stock May 29
President of Global Spine Business notifies of intention to sell stock May 28
Consensus EPS estimates fall by 81% May 16
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 10
Orthofix Medical Inc. Revises Sales Guidance for the Year 2023 May 10
Consensus revenue estimates decrease by 18% Mar 19
Full year 2022 earnings: EPS misses analyst expectations Mar 07
High number of new directors Feb 01
Orthofix Announces Full Commercial Launch and First Patient Cases of Mariner Deformity System Jan 27
Orthofix Medical Inc. Provides Unaudited Preliminary Net Sales Results Fourth Quarter and Full Year Ended December 31, 2022 Jan 10 Orthofix Medical Inc. Announces CEO Changes
Orthofix Medical Inc. Announces Publication of Data Demonstrating the Clinical Benefits of Trinity Elite Cellular Bone Allograft in Lumbar Fusion Procedures Dec 23
Two unknown private equity fund sponsors submitted a non-binding indication of interest to acquire Orthofix Medical Inc. (NasdaqGS:OFIX) for approximately $460 million. Dec 02
Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing Nov 19
Price target decreased to US$33.67 Nov 16
High number of new directors Nov 16
Consensus forecasts updated Nov 10
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 04
Orthofix Medical Inc. Provides Financial Guidance for the Full Year 2022 Nov 04
Orthofix Medical (NASDAQ:OFIX) Is In A Good Position To Deliver On Growth Plans Nov 01
Orthofix Medical Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 26
Orthofix Announces First Patient Implants with Legacy Demineralized Bone Matrix for Spine, Pelvic and Extremities Procedures Oct 14
Orthofix Medical Inc. (NasdaqGS:OFIX) entered into a definitive agreement to acquire SeaSpine Holdings Corporation (NasdaqGS:SPNE) for approximately $280 million in a merger of equals transaction. Oct 13
Consensus forecasts updated Oct 12
Orthofix Medical Inc. (NasdaqGS:OFIX) entered into a definitive agreement to acquire SeaSpine Holdings Corporation (NasdaqGS:SPNE) for approximately $280 million in a merger of equals transaction. Oct 12 Shareholder Returns OFIX US Medical Equipment US Market 7D -0.1% 1.0% -0.5% 1Y 29.9% 14.4% 24.3%
See full shareholder returns
Return vs Market: OFIX exceeded the US Market which returned 24.3% over the past year.
Price Volatility Is OFIX's price volatile compared to industry and market? OFIX volatility OFIX Average Weekly Movement 4.6% Medical Equipment Industry Average Movement 8.8% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.8% 10% least volatile stocks in US Market 3.3%
Stable Share Price: OFIX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OFIX's weekly volatility (5%) has been stable over the past year.
About the Company Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.
Show more Orthofix Medical Inc. Fundamentals Summary How do Orthofix Medical's earnings and revenue compare to its market cap? OFIX fundamental statistics Market cap US$712.69m Earnings (TTM ) -US$119.02m Revenue (TTM ) US$784.25m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) OFIX income statement (TTM ) Revenue US$784.25m Cost of Revenue US$228.40m Gross Profit US$555.85m Other Expenses US$674.88m Earnings -US$119.02m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
Earnings per share (EPS) -3.11 Gross Margin 70.88% Net Profit Margin -15.18% Debt/Equity Ratio 22.5%
How did OFIX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/31 02:09 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Orthofix Medical Inc. is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Gregory Chodaczek Boenning & Scattergood, Inc. Michael Gorman BTIG Caitlin Cronin Canaccord Genuity
Show 16 more analysts 
